NEW YORK (GenomeWeb News) – Shares of Compugen jumped 35 percent in early Monday trade on the Nasdaq after the firm announced that it had a new drug target for multiple epithelial tumors using its Monoclonal Antibody Targets Discovery Platform.

The firm's stock rose $1.42 to $5.50 within the first 20 minutes of the market's open. It was the second such spike in Compugen's stock within the past week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.